This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated quantitative and qualitative methods. The document is updated periodically and current as of December 7th, 2022, and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted...

The DEA’s Fentanyl Profiling Program (FPP) performs in-depth chemical analyses on fentanyl and fentanyl-related samples obtained from seizures throughout the United States. This report summarizes the findings for these analyses for Calendar Year 2021. FPP data is not intended to reflect U.S. market share, but is rather a snapshot of...

La DEA está observando un repunte en todo el país de sucesos de sobredosis masivas relacionados con el fentanilo que implican tres o más sobredosis que ocurren cerca en el tiempo en el mismo lugar. Solo en los dos últimos meses, al menos 7 eventos confirmados de sobredosis masiva en...

The DEA is seeing a nationwide spike in fentanyl-related mass-overdose events involving three or more overdoses occurring close in time at the same location. In just the past two months, there have been at least 7 confirmed mass overdose events across the United States resulting in 58 overdoses and 29...

DEA officials report a dramatic rise in the number of fake pills containing at least 2 mg of fentanyl, which is considered a deadly dose.

What is it? Many counterfeit pills are made to look like prescription opioids – such as oxycodone (Oxycontin®, Percocet®), hydrocodone (Vicodin®), and alprazolam (Xanax®); or stimulants like amphetamines (Adderall®) – but contain fentanyl or methamphetamine. Criminal drug networks are mass-producing fake pills and falsely marketing them as legitimate prescription pills...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and current as of June 21, 2021 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their entirety...

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 29, 2021 to September 28, 2023 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document...

The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic...

A comprehensive approach that will target the top drug threat identified by the local DEA division while continuing to focus on drug trafficking, violence, and crime reduction.